Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes: A 12-week Randomized Clinical Study

Trial Profile

Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes: A 12-week Randomized Clinical Study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Fatty liver; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms E-LIFT
  • Most Recent Events

    • 14 Jun 2017 Planned End Date changed from 1 May 2017 to 1 Aug 2017.
    • 14 Jun 2017 Status changed from completed to active, no longer recruiting.
    • 17 May 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top